Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2011-03-15
2011-03-15
Myers, Carla (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091200, C536S023500, C536S024310
Reexamination Certificate
active
07906283
ABSTRACT:
The invention provides a method of screening patients to identify those patients more likely to exhibit an increased risk of treatment-emergent suicidal ideation comprising: (a) obtaining a sample of genetic material from the patients, and (b) assaying the sample for the presence of a genotype in the patients which is associated with an increased risk of treatment-emergent suicidal ideation, wherein the genotype is characterized by a polymorphism in a gene selected from the group consisting of glutamine receptor, ionotropic, kainate 2 (GRIK2); glutamate receptor ionotropic AMPA 3 (GRIA3); and combinations thereof.
REFERENCES:
patent: 7083921 (2006-08-01), Murphy et al.
patent: 2004/0265825 (2004-12-01), Tartakovsky
patent: 2005/0069936 (2005-03-01), Diamond et al.
patent: 2006/0160119 (2006-07-01), Turner et al.
patent: 2007/0003931 (2007-01-01), Mrazek et al.
patent: 2008/0299125 (2008-12-01), Hinds et al.
Halushka et al. Nature. Jul. 1999. 22: 239-247.
Lucentini et al. The Scientist (2004) vol. 18, p. 20.
Wacholder et al . J. Natl. Cancer Institute (2004) 96(6):434-442.
Ioannidis et al. Nature genetics (2001) 29:306-309.
Kato et al. Neuropsychobiology. 2006.53: 186-195.
Menke et al. American Journal of Psychiatry. 2008. 165(7): 917-918.
Laje et al . American Journal of Psychiatry. 2007. 164: 1530-1538.
GeneCard for the PAPLN gene available via url: <genecards.org/cgi-bin/carddisp.pl?gene=Papln&snp=299#snp>, printed on Dec. 15, 2009.
GeneCard for the IL28RA gene available via url: <genecards.org/cgi-bin/carddisp.pl?gene=II28ra&snp=284#snp>, printed on Dec. 15, 2009.
Thisted, R.A. May 25, 1998; available online via url: <stat.uchicago.edu/˜thisted>, pp. 1-6.
Laje et al. American Journal of Human Genetics. 141B, Issue 7, pp. 724-725, abstract O22.3, available online Sep. 11, 2006.
Choi et al.,Neuropsychobiology, 52, 155-162 (2005).
Lipsky et al.,Neuropsychopharmacology, 31(No. Suppl. 1), S23-S24 (2006).
McMahon,American Journal of Medical Genetics, 141B(No. 7), 689-690 (2006).
McMahon,Neuropsychopharmacology, 31(No. Suppl. 1), S38-S39 (2006).
Murphy et al.,American Journal Psychiatry, 160(10), 1830-1835 (2003).
GenBank Accession No. AAH32004 (Jul. 15, 2006).
GenBank Accession No. AAH37954 (Sep. 1, 2006).
GenBank Accession No. BC032004 (Jul. 15, 2006).
GenBank Accession No. BC037954 (Sep. 1, 2006).
GenBank Accession No. NM—000827 (Sep. 24, 2007).
GenBank Accession No. NM—000828 (Sep. 17, 2007).
GenBank Accession No. NM—000833 (Sep. 25, 2007).
GenBank Accession No. NM—001018064 (Oct. 28, 2007).
GenBank Accession No. NM—006028 (Sep. 3, 2007).
GenBank Accession No. NM—021956 (Oct. 22, 2007).
GenBank Accession No. NM—170743 (Sep. 25, 2007).
GenBank Accession No. NM—173462 (Jun. 26, 2007).
Mann et al., “ACNP Task Force report on SSRIs and suicidal behavior in youth,”Neuropsychopharmacology, 31 (3), 473-492 (2006).
McMahon et al., “Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment,”Am. J. Hum. Genet., 78, 804-814 (2006).
Rush et al., “Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design,”Control Clin. Trials, 25 (1), 119-142 (2004).
Trivedi et al., “Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice,”Am. J. Psychiatry, 163 (1), 28-40 (2006).
Laje Gonzalo E.
Manji Husseini K.
McMahon Francis J.
Paddock Silvia
Rush A. John
Board of Regents , The University of Texas System
Leydig & Voit & Mayer
Myers Carla
The United States of America as represented by the Department of
LandOfFree
Methods to identify patients at risk of developing adverse... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods to identify patients at risk of developing adverse..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods to identify patients at risk of developing adverse... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2722066